Abstract-Walker-Warburg syndrome (WWS) is a congenital muscular dystrophy associated with neuronal migration disorder and structural eye abnormalities. The mutations in the O-mannosyltransferase 1 gene (POMT1) were identified recently in 20% of patients with WWS. The authors report on a patient with WWS and a novel POMT1 mutation. Their patient expressed ␣-dystroglycan (␣-DG) core protein, but fully glycosylated ␣-DG antibody epitopes were absent, associated with the loss of laminin-binding activity.
Walker-Warburg syndrome (WWS; MIM 236670), Fukuyama-type congenital muscular dystrophy (FCMD; MIM 253800), and muscle-eye-brain disease (MEB; MIM 253280) are closely related congenital muscular dystrophies (CMDs) with cobblestone lissencephaly and eye abnormalities. Although they are known to be caused by the mutations of different genes encoding putative glycosyltransferases, 1 it now is clear that the mutations of each gene produce overlapping clinical phenotypes. 2, 3 In addition, they share a similar pattern of selective loss of ␣-dystroglycan (␣-DG) on immunohistochemical study. 1 A recent study showed hypoglycosylation of ␣-DG and loss of binding activity of ␣-DG to laminin, neurexin, and agrin in FCMD, MEB, and the mutant myodystrophy (Large myd ) mouse, suggesting a defect in the same post-translational modification pathway of glycosylation in ␣-DG. 4 Mutations in the O-mannosyltransferase 1 gene (POMT1) were implicated recently in 20% of patients with WWS. 5 The laminin-binding site in ␣-DG is thought to reside in O-mannosyl-linked carbohydrate side chains, which may require POMT1 for synthesis. 6 We report our experience with a Japanese boy with WWS and a novel POMT1 mutation, who showed reduced glycosylation and loss of lamininbinding activity of ␣-DG in skeletal muscle.
Methods. Patient. The patient was a Japanese boy aged 3.5 years from apparently nonconsanguineous parents. No other family member was affected. Prenatal ultrasonography showed that the patient had a meningoencephalocele. He was born at gestational week 38 by Cesarean section with a body weight of 2,042 g. He was floppy with an enlarged head. He underwent surgery to remove a meningoencephalocele, and a ventriculoperitoneal shunt was added 21 days after birth. Mild microphthalmia and corneal clouding also were observed. Serum creatine kinase levels were markedly elevated to 600 to 31,000 IU/L (upper normal limit, 70 IU/L). He exhibited markedly delayed milestones. He could not control his head, roll over, or sit. He showed lack of facial expression with an inability to smile and never developed the ability to speak. Brain MRI revealed agyric frontal and temporo-occipital lobes mixed with pachygyric parietal cortex. Hypoplasia of brain stem and cerebellum also was observed (figure 1). EEG showed multifocal spikes, and the muscle biopsy showed marked increase in fatty tissue with evidence of necrosis and regeneration. The mutational analysis for fukutin and protein O-mannose ␤-1,2-Nacetylglucosaminyl-transferase gene (POMGnT1) did not show any abnormalities.
Immunohistochemistry and immunoblotting studies. The following antibodies were used: monoclonal anti-␣-DG (VIA4-1, Upstate Biotechnology, Lake Placid, NY), polyclonal goat anti-␣-DG (GT20ADG), 4 monoclonal anti-␤-DG (43DAG1/8D5, Novocastra Laboratories, Newcastle upon Tyne, UK), monoclonal antilaminin-␣2 chain (5H2, Chemicon, Temecula, CA), monoclonal antidystrophin C-terminal (Dy8/6C5, Novocastra Laboratories), and monoclonal antisarcoglycan antibodies (Novocastra Laboratories). The detailed techniques of the immunohistochemistry, immunoblotting, and laminin overlay assays have been described previously. 4, 7 Mutation analysis. Genomic DNA was extracted from frozen muscle tissue using standard method with informed consent. Primer pairs were designed to amplify all coding exons and flanking intronic sequences of POMT1. The amplified products were sequenced using an ABI PRISM 3100 (Applied Biosystems, Foster City, CA). For the detection and screening of L421del (1260 to 1262 delCCT) in exon 13 of POMT1, primers F-CAGTAGCAGCAACTCATGGG, R-ACGGT-TGTGGCTGCTATAGC, and restriction enzyme AvaI were used. One hundred healthy Japanese individuals served as control subjects.
Results. Immunohistochemical and immunoblotting
analyses. The immunohistochemical analysis revealed an almost complete loss of immunoreactivity with VIA4-1 anti-␣-DG antibody in the patient, whereas anti-␣-DG core protein GT20ADG showed membrane staining in each muscle fiber (figure 2). Immunoreaction against the laminin-␣2 chain was reduced slightly, but ␤-DG (see figure 2), dystrophin, and sarcoglycans (not shown) were well preserved.
Immunoblotting analysis using GT20ADG showed a band with a reduced molecular mass, whereas VIA4-1 showed no detectable band for ␣-DG in the patient ( figure  3, A and B) . The molecular weight shift observed in our patient (Ͼ60 kDa) was almost identical to those reported in FCMD and MEB. 4 On laminin overlay assay, the patient's muscle showed an almost complete loss of lamininbinding activity of ␣-DG ( figure 3C) .
Mutation analysis. We found a homozygous deletion of three base pairs (1260 to 1262 delCCT) in POMT1, which is expected to delete single amino acid leucine at position 421 (see figure E-1A on the Neurology Web site). No identical mutation was present in 100 normal Japanese control subjects (see figure E-1B on the Neurology Web site). The amino acid sequence alignment showed that the deleted amino acid leucine and surrounding primary sequence are highly conserved among different species (see figure E-1C on the Neurology Web site).
Discussion. In this study, we identified a deletion of the single amino acid leucine at position 421 of POMT1 from the patient's DNA. This is considered to be a causative mutation for several reasons. First, the same change was not found among 100 Japanese control subjects. Next, the deleted amino acid leucine is located within a highly conserved region of the gene and is conserved among different species. A previously reported V428D mutation also is only seven amino acids downstream to ours. 5 These findings suggest that this conserved region plays an important role in the proper function of the protein.
Our patient showed exceptionally long survival for WWS because most patients with WWS die during infancy and rarely survive beyond age 3 years. Because complete agyria is common in patients with WWS, the pattern of the cortical dysplasia in our patient-agyria mixed with parietal pachygyria in MRI-could be considered milder than typical WWS. Thus, our patient showed intermediate phenotype between WWS and MEB in terms of clinical severity and MRI finding. However, the diagnosis of WWS seems more accurate than MEB or FCMD in our patient because he had a meningoencephalocele, which is almost exclusively seen in WWS. 8 There are some recent reports documenting the remarkable clinical variability originating from the mutation of the same genes causing CMDs, and thus, it is possible for POMT1 mutations to produce a more benign WWS phenotype like that seen in our patient. 2, 3, 9 Although the immunoreactivity against the antibody VIA4-1 was lost completely in our patient, the reaction against the antibody GT20ADG was well preserved. Because the antibody GT20ADG recognizes the core protein of ␣-DG, our results indicate that ␣-DG localizes at the surface membrane of skeletal muscle but that the epitope for VIA4-1 antibody was specifically disrupted or masked. 4 Because the antibody VIA4-1 is thought to recognize, at least in part, the carbohydrate epitope of ␣-DG, the glycosylation status of ␣-DG is likely to be altered in our patient. 4 The results of immunoblotting and laminin overlay assays further support this speculation. The ␣-DG from normal skeletal muscle is a heavily glycosylated protein with a molecular weight of 156 kDa. Thus, the reduction of molecular weight, seen only by GT20ADG, is likely to be related to the loss of glycoconjugates from ␣-DG. Accordingly, the loss of laminin-binding activity shown in the laminin overlay assay most likely is caused by the loss of glycoconjugate, which is thought to be a laminin-binding ligand of ␣-DG.
6 A brain-selective deletion of dystroglycan in mice was shown recently to cause CMDlike brain malformations and defective laminin binding, giving strong evidence that abnormalities of dystroglycan underlie the neuronal migration disorder seen in this group of disorders. 10 Because similar pattern of glycosylation-deficient disruption of dystroglycan function has been observed in FCMD, MEB, and Large myd mice, 4 it is likely that WWS shares a similar pathomechanism with them. In addition, the complete loss of the laminin-binding activity of ␣-DG in our patient with WWS is almost identical to that observed in FCMD.
